Lung Cancer

Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors,...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Formáid: Online
Teanga:Béarla
Foilsithe / Cruthaithe: IntechOpen 2023
Ábhair:
Rochtain ar líne:ONIX_20231201_9781789843507_1315
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
_version_ 1869514605393346560
collection Directory of Open Access Books
description Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors, and mechanisms involved in initiation and tumor progression, important improvements have occurred in diagnostics and therapeutics in the shape of advances in molecular genotyping, procedures for sampling, new potential, and less invasive sources of samples for the diagnosis and development of new targeted therapies. The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer.
format Online
id doab-20.500.12854ir-130206
institution Directory of Open Access Books
language eng
publishDate 2023
publishDateRange 2023
publishDateSort 2023
publisher IntechOpen
publisherStr IntechOpen
record_format ojs
spelling doab-20.500.12854ir-1302062024-03-31T22:45:50Z Lung Cancer Fabiola Costa Torres, Alba immunotherapy, biomarker, metabolomics, epigenetic, cancer stem cells, methylation thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Among the deadliest type of cancers, lung cancer faces several challenges in diagnosis and treatment: late diagnosis and misdiagnosis, inadequate tumor sampling, and resistance development to current therapies, among others. Together with advances in the understanding of molecular features, factors, and mechanisms involved in initiation and tumor progression, important improvements have occurred in diagnostics and therapeutics in the shape of advances in molecular genotyping, procedures for sampling, new potential, and less invasive sources of samples for the diagnosis and development of new targeted therapies. The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer. 2023-12-01T17:04:06Z 2023-12-01T17:04:06Z 2018 book ONIX_20231201_9781789843507_1315 9781789843507 9781789843491 9781838816391 https://directory.doabooks.org/handle/20.500.12854/130206 eng image/jpeg n/a https://www.intechopen.com/books/6676 https://mts.intechopen.com/storage/books/6676/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/intechopen.71993 10.5772/intechopen.71993 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781789843507 9781789843491 9781838816391 IntechOpen 204 open access
spellingShingle immunotherapy, biomarker, metabolomics, epigenetic, cancer stem cells, methylation
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
Lung Cancer
title Lung Cancer
title_full Lung Cancer
title_fullStr Lung Cancer
title_full_unstemmed Lung Cancer
title_short Lung Cancer
title_sort lung cancer
topic immunotherapy, biomarker, metabolomics, epigenetic, cancer stem cells, methylation
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
topic_facet immunotherapy, biomarker, metabolomics, epigenetic, cancer stem cells, methylation
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
url ONIX_20231201_9781789843507_1315